Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil
WOODCLIFF LAKE, N.J. and SAN DIEGO , Dec. 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc. , has received regulatory approval from the Brazilian Health Surveillance Agency (ANVISA) for
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Dec. 13, 2016 /PRNewswire/ --  Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that Amit Munshi , the Company's President and Chief Executive Officer will present a corporate update at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 9:00am PT
View HTML
Toggle Summary Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
SAN DIEGO , Dec. 7, 2016 /PRNewswire/ --  Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that it has completed enrollment in the ralinepag phase 2 trial.  Ralinepag is an oral, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial
View HTML
Toggle Summary Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference
SAN DIEGO , Nov. 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that four abstracts will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference on Friday, December 9 at 6:00pm
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
SAN DIEGO , Nov. 9, 2016 /PRNewswire/ --  Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that Amit Munshi , the Company's President and Chief Executive Officer will present a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 at 1:30pm ET
View HTML
Toggle Summary Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016
SAN DIEGO , Nov. 9, 2016 /PRNewswire/ --  Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that Professor Lucie Clapp will present a poster at the American Heart Association (AHA) Scientific Sessions 2016 on Monday, November 14 at 10:45am CT .  The scientific sessions are taking place
View HTML
Toggle Summary Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting
WOODCLIFF LAKE, N.J. and SAN DIEGO , Nov. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ ® (lorcaserin HCl) CIV.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting
SAN DIEGO , Oct. 11, 2016 /PRNewswire/ --  Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET .  The meeting is
View HTML
Toggle Summary Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
New FDA-Approved Formulation Offers Patients a Once-Daily Dosing Option for Chronic Weight Management
View HTML
Toggle Summary Arena Pharmaceutics Announces Formation of Beacon Discovery
SAN DIEGO , Sept. 1, 2016 /PRNewswire/ --  Arena Pharmaceuticals, Inc. ( NASDAQ : ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"), an independent, privately-held drug discovery incubator.  Beacon will focus on identifying and advancing molecules targeting G-Protein Coupled
View HTML